Selank
- Category
- Brain & Cognition
- Administration routes
- Nasal
- Regulatory status
- Not FDA-approved
What it is
A synthetic, stabilized analog of the immune peptide tuftsin, used intranasally mainly for anxiety, focus, and immunity. Its anxiolytic and anti-inflammatory effects have the most support, but human trials are almost all Russian, small, and short (7 to 21 days). The FDA has flagged immunogenicity, with no pregnancy, lactation, or pediatric data. Not an approved US drug, and most supply outside Russia is unregulated research-grade material.
Read Full recordStudied uses & evidence
Studied uses(6)
Anxiolytic effects comparable to benzodiazepines without their side effects
MediumSmall human trials found anxiety relief comparable to benzodiazepines, without sedation or dependence.
Neuroprotection and cognitive enhancement via BDNF elevation
LowThe cited rat study found preserved memory and prevention of an ethanol-induced BDNF increase; human cognitive benefit remains unestablished.
Anti-inflammatory and immunomodulatory effects
MediumA human study showed shifted cytokine levels; clinical anti-inflammatory benefit remains unproven.
Evidence limits
- Evidence Level
- Moderate
Selank's clinical evidence base is moderate but geographically concentrated. The primary human evidence comes from Russian clinical trials: an RCT in 62 GAD/neurasthenia patients showing anxiolytic efficacy comparable to medazepam without benzodiazepine side effects (Zozulia et al. 2008); a clinical evaluation in 20 GAD patients identifying rapid and slow responder subtypes with significant HARS score reductions (Syunyakov et al. 2012); and immunomodulatory effects documented in anxiety patients showing IL-6 suppression and Th1/Th2 rebalancing (Uchakina et al. 2008). Preclinical evidence is substantially more extensive, with well-designed studies demonstrating BDNF elevation, GABAergic gene modulation, anti-inflammatory cytokine regulation, neuroprotection against ethanol-induced cognitive impairment, and attenuation of opioid withdrawal. The major gaps are the absence of large international RCTs replicating the Russian clinical findings, no long-term safety studies beyond 14-21 day treatment courses, and no clinical trials specifically targeting aging or longevity outcomes.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Severe hypotension
ModerateSelank's anxiolytic effects may further lower blood pressure.
General cautions
Pregnancy
AbsoluteNo reproductive safety data outside Russia.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Most clinical studies examine only 7-21 day treatment periods
ModerateFDA cited immunogenicity as a safety concern
ModerateMild nasal or throat irritation (intranasal)
LowRare mild dizziness
LowNo safety data in pregnancy, lactation, or children
ModerateMostly research-grade outside Russia/Ukraine
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.